GABA-A receptor; anion channel · PROTEIN COMPLEX GROUP · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13GABA-A receptor; anion channel shows approved-linked disease relevance led by anxiety. 5 more disease programs remain visible in the same review block. 18 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P14867. Start with anxiety, then reuse UniProt P14867 as the stable protein anchor across project notes and exports.
Start with anxiety, then reuse UniProt P14867 as the stable protein anchor across project notes and exports.
GABA-A receptor; anion channel shows approved-linked disease relevance led by anxiety. 5 more disease programs remain visible in the same review block. 18 linked drugs remain visible in the same block.
Start review with anxiety because it currently carries approved-linked support. Linked drugs include ALPRAZOLAM, CHLORDIAZEPOXIDE, CLOBAZAM, CLOMETHIAZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGamma-aminobutyric acid receptor subunit alpha-1
Review this target as GABA-A receptor; anion channel, mapped to UniProt P14867. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit alpha-1. Sequence length is 456 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats GABA-A receptor; anion channel as ChEMBL target CHEMBL2093872, mapped to UniProt P14867. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether GABA-A receptor; anion channel is the right protein anchor across sources, using UniProt P14867 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why anxiety is currently framed as approved-linked support. It currently carries 18 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | GABA-A receptor; anion channel |
| Target Type | PROTEIN COMPLEX GROUP |
| Organism | Homo sapiens |
| UniProt | P14867 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Gamma-aminobutyric acid receptor subunit alpha-1 |
| UniProt Accession | P14867 |
| Component Type | Protein |
| Sequence Length | 456 aa |
Gamma-aminobutyric acid receptor subunit alpha-1
Review this target as GABA-A receptor; anion channel, mapped to UniProt P14867. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit alpha-1. Sequence length is 456 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
GABA-A receptor; anion channel shows approved-linked disease relevance led by anxiety. 5 more disease programs remain visible in the same review block.
Start review with anxiety because it currently carries approved-linked support. Linked drugs include ALPRAZOLAM, CHLORDIAZEPOXIDE, CLOBAZAM, CLOMETHIAZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3144739 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL309517 | 9.8 | IC50 | 0.16 | Preclinical |
| CHEMBL4747460 | 9.7 | IC50 | 0.2 | Preclinical |
| CHEMBL79037 | 9.62 | IC50 | 0.24 | Preclinical |
| CHEMBL19732 | 9.4 | IC50 | 0.3981 | Preclinical |
| CHEMBL1271047 | 9.4 | IC50 | 0.4 | Preclinical |
| CHEMBL78730 | 9.34 | IC50 | 0.46 | Preclinical |
| CHEMBL76263 | 9.31 | IC50 | 0.49 | Preclinical |
| CHEMBL49141 | 9.3 | IC50 | 0.5 | Preclinical |
| CHEMBL1518572 | 9.3 | IC50 | 0.5 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein complex format | 119 | 251 | 6.9 |
| assay format | 21 | 108 | 6.8 |
| tissue-based format | 19 | 30 | 7.6 |
| cell membrane format | 2 | 36 | 6.0 |
| cell-based format | 2 | 9 | 6.9 |
| organism-based format | 1 | 23 | 6.4 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 9 | 32 | 6.9 |
| tissue-based format | 6 | 12 | 7.2 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 3 | 1 | 5.3 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein complex format | 1 | 0 | — |